SGMO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Sangamo Therapeutics Inc (SGMO) is not a good buy for a beginner investor with a long-term strategy at this time. The company's financial performance is extremely weak, with significant revenue and net income declines. Additionally, there are no positive trading signals, news catalysts, or strong technical indicators to support a buy decision. The options data reflects a lack of significant bullish sentiment, and the stock's long-term prospects appear uncertain.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 59.56, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 0.436, with resistance at 0.511 and support at 0.362. Overall, technical indicators suggest no strong buy signals.
NULL. There are no recent news events, congress trading data, or significant insider or hedge fund activity to act as positive catalysts.
Additionally, the stock has a 50% chance of declining -10.29% in the next week based on historical candlestick patterns.
In Q3 2025, Sangamo Therapeutics reported a revenue drop of -98.82% YoY to $581,000, a net income decline of -472.19% YoY to -$34.93 million, and an EPS drop of -375.00% YoY to -0.11. While gross margin remained at 100%, the overall financial performance is extremely weak.
No recent analyst ratings or price target changes are available for SGMO, leaving no clear guidance from Wall Street analysts.
